Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

被引：0
|
作者：
Hamadani, Mehdi
Graham, Christopher N.
Liao, Laura
Zhang, Katherine H.
Strat, Hannah
Ungar, David
Ai, Weiyun Z.
Chen, Lei
Carlo-Stella, Carmelo
机构：
[1] BMT & Cellular Therapy Program, Med Coll Wisconsin, Milwaukee, WI USA
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] ADC Therapeut Inc, New Providence, NJ USA
[4] ADC Therapeut Amer Inc, Clin Dev, Murray Hill, NJ USA
[5] Univ Calif San Francisco, Div Hematol & Oncol, Dept Med, San Francisco, CA USA
[6] Humanitas Res Hosp, Rozzano, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19551
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Long-Term Survival Projections of Loncastuximab Tesirine-Treated Patients in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Hamadani, Mehdi
    Graham, Christopher
    Liao, Laura
    Zhang, Kate
    Strat, Hannah
    Ungar, David
    Ai, Weiyun
    Chen, Lei
    Carlo-Stella, Carmelo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S373 - S373
  • [2] Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Juarez-Salcedo, Luis Miguel
    Nimkar, Santosh
    Corazon, Ana Maria
    Dalia, Samir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [3] Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
    Xu, Bo
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (05) : 707 - 719
  • [4] Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
    Bo Xu
    European Journal of Clinical Pharmacology, 2022, 78 : 707 - 719
  • [5] Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma
    Goparaju, Krishna
    Caimi, Paolo F.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (11) : 1373 - 1381
  • [6] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
    Furqan, Fateeha
    Hamadani, Mehdi
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [7] Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
    Hamadani, Mehdi
    Linhares, Yuliya
    Gandhi, Mitul
    Chung, Michael
    Adamis, Helena
    Ungar, David
    Carlo-Stella, Carmelo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Dyer, Martin J. S.
    De Vos, Sven
    Ruan, Jia
    Flowers, Christopher
    Maddocks, Kami J.
    Rule, Simon
    Hamdy, Ahmed M.
    Izumi, Raquel
    Slatter, J. Greg
    Cheung, Jean
    Frigualt, Melanie M.
    Wei, Helen
    Mourya, Sanchita
    Hunder, Naomi N. H.
    Fowler, Nathan Hale
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Loncastuximab tesirine for diffuse large B-cell lymphoma
    Zurko, J.
    Hamadani, M.
    DRUGS OF TODAY, 2021, 57 (12) : 733 - 743
  • [10] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a profile of its use in the USA
    Anthony Markham
    Zaina T. Al-Salama
    Drugs & Therapy Perspectives, 2022, 38 : 261 - 267
12345